Stryker Corporation (NYSE:SYK) and Uroplasty (UPI) Financial Survey – Stock Observer

Stryker Corporation (NYSE: SYK) and Uroplasty (NYSE:UPI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitabiliy and risk.

Profitability

This table compares Stryker Corporation and Uroplastys net margins, return on equity and return on assets.

Insider and Institutional Ownership

74.3% of Stryker Corporation shares are owned by institutional investors. 7.4% of Stryker Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Stryker Corporation and Uroplasty, as provided by MarketBeat.

Stryker Corporation presently has a consensus price target of $142.79, indicating a potential downside of 3.39%. Given Stryker Corporations higher probable upside, equities analysts clearly believe Stryker Corporation is more favorable than Uroplasty.

Dividends

Stryker Corporation pays an annual dividend of $1.70 per share and has a dividend yield of 1.2%. Uroplasty does not pay a dividend. Stryker Corporation pays out 37.9% of its earnings in the form of a dividend. Stryker Corporation has raised its dividend for 6 consecutive years.

Valuation & Earnings

This table compares Stryker Corporation and Uroplastys gross revenue, earnings per share (EPS) and valuation.

Stryker Corporation has higher revenue and earnings than Uroplasty.

Summary

Stryker Corporation beats Uroplasty on 10 of the 11 factors compared between the two stocks.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Companys segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Companys products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.

Uroplasty Company Profile

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Companys products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

View post:

Stryker Corporation (NYSE:SYK) and Uroplasty (UPI) Financial Survey - Stock Observer